Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01663272 · ClinicalTrials.gov registry record · Phase 1

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer, sponsored by University of Michigan Rogel Cancer Center.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT01663272 is a Phase 1 study of Pancreatic Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 12 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01663272, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory experiments, especially when given with gemcitabine. Initial studies with cabozantinib in pancreatic cancer have shown some activity against the disease. The purpose of this study is to determine the safest and highest dose of cabozantinib that can be given together with standard doses of gemcitabine in patients with pancreatic cancer. This study will determine the safety and tolerability of this two drug combination.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG gemcitabine
  • DRUG CABOZANTINIB

Study Locations (1)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2012-07
Est. Completion 2017-03-01
Phase Phase 1

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01663272

The ClinicalTrials.gov registry entry for NCT01663272 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.

NCT01663272 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT01663272 about?

NCT01663272 is a clinical study titled "A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer". Gemcitabine is considered one of the standard drugs for advanced pancreatic cancer and is approved by the FDA to treat it. Cabozantinib is a new drug that has demonstrated effectiveness against pancreatic cancer in laboratory experiments, especially when given with gemcitabine. Initial studies with ...

What is the current status of trial NCT01663272?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-07. Estimated completion is 2017-03-01.

What conditions does trial NCT01663272 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT01663272?

The interventions under investigation include: gemcitabine (DRUG), CABOZANTINIB (DRUG).

Who is sponsoring clinical trial NCT01663272?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01663272 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.